Page 33 - Merck Sharp News Today

The Pharmaceutical Journal from the Royal Pharmaceutical Society

CHICAGO — Adjuvant pembrolizumab showed durable benefit vs. placebo among patients with resected stage IIB or IIC melanoma, according to randomized phase 3 study results presented at ASCO Annual Meeting.After more than 3 years of follow-up, patients assigned the anti-PD-1 therapy achieved significantly longer distant metastasis-free survival (DMFS) and RFS, results of the KEYNOTE-716 trial

Patients who are diagnosed with axial spondyloarthritis after referral to a rheumatologist for chronic back pain most often keep that diagnosis, providing good reason to refer patients early.

Deca Durabolin, known as nandrolone decanoate, is an intriguing compound that has captivated the world of fitness and bodybuilding.

/PRNewswire/ -- DelveInsights Monoclonal Antibodies Competitive Landscape – 2023 report provides comprehensive global coverage of available, marketed, and...

CHICAGO — A chemotherapy de-escalation strategy involving dual HER2 blockade resulted in high rates of 3-year invasive DFS among patients with HER2-positive early breast cancer, according to study results presented at ASCO Annual Meeting.The findings appeared consistent with those of studies that explored a combination of neoadjuvant chemotherapy and dual HER2-targeted treatments, with no

Results of a phase 3 trial in Chinese patients with systemic lupus erythematosus showed a significantly greater response rate with telitacicept, compared with placebo.

In a phase 2 clinical trial of the immune checkpoint inhibitor pembrolizumab, investigators found that 42 percent of patients with metastatic brain cancer benefited from the therapy, with seven patients in the trial surviving longer than two years.

/PRNewswire/ -- The "Advanced Renal Cell Carcinoma - Pipeline Insight, 2023" drug pipelines has been added to ResearchAndMarkets.coms offering. This report...

Researchers discovered that 42 percent of patients with metastatic brain cancer benefited from the immune checkpoint inhibitor pembrolizumab in a phase 2 clinical study, with seven patients living for more than two years